Consistent with and extending our in situ findings in clinical patients, Nrp2 was also expressed in profibrotic, osteogenic and inflammatory MSC and osteolineage cells in murine myelofibrosis models [8] by scRNAseq analysis (Figure 4), supporting its possible role as a druggable target in MPN. The gene discussed is NRP2; the disease is myeloproliferative disorder.